Your browser is no longer supported. Please, upgrade your browser.
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.17 Insider Own0.30% Shs Outstand60.79M Perf Week1.00%
Market Cap3.59B Forward P/E- EPS next Y-8.72 Insider Trans-8.04% Shs Float56.50M Perf Month30.70%
Income-484.10M PEG- EPS next Q-2.53 Inst Own94.80% Short Float4.18% Perf Quarter-12.15%
Sales0.06M P/S62979.02 EPS this Y-196.10% Inst Trans1.28% Short Ratio4.73 Perf Half Y-21.76%
Book/sh15.98 P/B3.75 EPS next Y4.10% ROA-40.90% Target Price95.25 Perf Year-15.99%
Cash/sh16.20 P/C3.69 EPS next 5Y- ROE-45.00% 52W Range45.50 - 90.19 Perf YTD-22.09%
Dividend- P/FCF- EPS past 5Y-9.90% ROI-36.70% 52W High-33.63% Beta0.48
Dividend %- Quick Ratio15.30 Sales past 5Y-52.60% Gross Margin- 52W Low31.56% ATR2.14
Employees363 Current Ratio15.30 Sales Q/Q- Oper. Margin- RSI (14)58.31 Volatility3.25% 4.23%
OptionableYes Debt/Eq0.04 EPS Q/Q-49.30% Profit Margin- Rel Volume0.62 Prev Close61.05
ShortableYes LT Debt/Eq0.04 EarningsAug 05 AMC Payout- Avg Volume499.42K Price59.86
Recom1.70 SMA207.01% SMA503.56% SMA200-11.66% Volume315,041 Change-1.95%
May-18-21Initiated Goldman Buy $90
Apr-27-21Initiated Citigroup Buy $104
Apr-26-21Resumed Credit Suisse Outperform $102
Nov-10-20Reiterated Guggenheim Buy $115 → $105
Sep-14-20Resumed JP Morgan Overweight $71
Jun-29-20Initiated H.C. Wainwright Buy $90
May-18-20Initiated Jefferies Buy $62
Mar-31-20Initiated Guggenheim Buy $95
Mar-26-20Upgrade BofA/Merrill Neutral → Buy $47 → $56
Jan-31-20Upgrade JP Morgan Neutral → Overweight $58
Nov-13-19Initiated BofA/Merrill Neutral $51
Dec-13-18Initiated Berenberg Buy $55
May-31-18Initiated RBC Capital Mkts Outperform $65
Mar-21-18Upgrade Needham Hold → Buy $60
Mar-20-18Reiterated JMP Securities Mkt Outperform $63 → $79
Jan-18-18Resumed Credit Suisse Outperform $44
Jan-18-18Initiated Credit Suisse Outperform $44
Jan-03-18Upgrade Wells Fargo Market Perform → Outperform
Jul-11-17Reiterated Citigroup Buy $23 → $37
Jul-07-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Sep-17-21 04:05PM  
Sep-02-21 04:56PM  
Aug-27-21 05:33PM  
Aug-23-21 08:02PM  
Aug-18-21 04:05PM  
Aug-16-21 11:17AM  
Aug-06-21 09:00AM  
Aug-05-21 07:25PM  
Jul-29-21 04:05PM  
Jul-28-21 06:58AM  
Jul-27-21 04:05PM  
Jul-22-21 04:05PM  
Jul-19-21 08:30AM  
Jul-06-21 10:30AM  
Jun-18-21 04:05PM  
Jun-15-21 04:20PM  
Jun-14-21 08:30AM  
Jun-10-21 10:19AM  
Jun-09-21 10:03AM  
Jun-08-21 08:30AM  
Jun-05-21 03:11AM  
Jun-04-21 11:31AM  
Jun-03-21 08:30AM  
May-19-21 05:30PM  
May-17-21 01:55AM  
May-12-21 08:30AM  
May-06-21 10:42AM  
May-05-21 07:05PM  
Apr-28-21 04:05PM  
Apr-23-21 10:10AM  
Apr-19-21 04:05PM  
Apr-16-21 06:35PM  
Mar-29-21 03:09PM  
Mar-25-21 11:30AM  
Mar-19-21 08:30AM  
Mar-16-21 08:03AM  
Mar-03-21 12:40PM  
Mar-02-21 04:05PM  
Feb-24-21 06:54AM  
Feb-23-21 04:41PM  
Feb-22-21 10:29AM  
Feb-18-21 04:05PM  
Feb-16-21 04:05PM  
Feb-11-21 12:15AM  
Feb-07-21 02:13PM  
Feb-02-21 09:05AM  
Jan-22-21 04:04PM  
Dec-22-20 04:01PM  
Dec-18-20 01:01PM  
Dec-14-20 07:16PM  
Dec-11-20 09:00AM  
Dec-08-20 08:30AM  
Nov-30-20 04:05PM  
Nov-24-20 08:30AM  
Nov-19-20 05:59PM  
Nov-13-20 05:25AM  
Nov-10-20 02:27PM  
Nov-09-20 10:00PM  
Nov-06-20 10:18AM  
Nov-02-20 08:30AM  
Oct-28-20 08:30AM  
Oct-27-20 12:30PM  
Oct-20-20 04:01PM  
Oct-09-20 04:30PM  
Oct-01-20 10:22AM  
Sep-18-20 04:01PM  
Sep-16-20 08:30AM  
Sep-11-20 09:59AM  
Sep-09-20 10:40AM  
Sep-04-20 11:41AM  
Sep-03-20 04:01PM  
Sep-01-20 08:30AM  
Aug-19-20 04:01PM  
Aug-05-20 04:01PM  
Jul-29-20 04:01PM  
Jul-17-20 04:01PM  
Jul-13-20 02:33PM  
Jul-12-20 12:02PM  
Jun-18-20 04:01PM  
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Munshi AmitPresident and CEOAug 16Buy48.191,00048,19039,550Aug 17 08:30 AM
Munshi AmitPresident and CEOAug 12Buy50.411,00050,41038,550Aug 13 08:10 AM
Munshi AmitPresident and CEOAug 10Buy52.911,00052,91537,550Aug 11 08:04 AM
Lisicki RobertEVP, Chief Commercial OfficerAug 03Option Exercise40.9517,500716,62533,601Aug 05 06:08 PM
Lisicki RobertEVP, Chief Commercial OfficerAug 03Sale60.0817,5001,051,48216,101Aug 05 06:08 PM
Dallas Jayson Donald AlexanderDirectorJun 15Sale66.361,22381,1587,152Jun 15 05:27 PM
Schmidt JoanEVP, General Counsel & SecMar 15Option Exercise0.0012,600019,475Apr 02 08:10 PM
Aurentz VincentExecutive VP and CBOFeb 16Option Exercise14.802,52437,35429,524Feb 18 09:00 PM
Aurentz VincentExecutive VP and CBOFeb 16Sale85.002,524214,54027,000Feb 18 09:00 PM
Lisicki RobertEVP, Chief Commercial OfficerFeb 02Option Exercise40.9517,500716,62526,941Feb 04 08:57 PM
Lisicki RobertEVP, Chief Commercial OfficerFeb 02Sale78.8717,5001,380,3089,441Feb 04 08:57 PM
Munshi AmitPresident and CEOJan 19Option Exercise15.5050,000775,00057,750Jan 20 09:05 PM
Dallas Jayson Donald AlexanderDirectorJan 19Sale80.501,327106,8245,308Jan 20 09:06 PM
Munshi AmitPresident and CEOJan 19Sale80.1450,0004,006,7607,750Jan 20 09:05 PM
Munshi AmitPresident and CEOJan 15Option Exercise15.5050,000775,00057,750Jan 20 09:05 PM
Munshi AmitPresident and CEOJan 15Sale80.2450,0004,011,9767,750Jan 20 09:05 PM
Munshi AmitPresident and CEOJan 12Sale75.1214,8771,117,5697,750Jan 14 08:43 PM
Lisicki RobertEVP, Chief Commercial OfficerJan 07Option Exercise0.0012,600012,600Jan 11 09:19 PM
Aurentz VincentExecutive VP and CBOJan 07Option Exercise0.0018,000027,000Jan 11 09:18 PM
Munshi AmitPresident and CEOJan 07Option Exercise0.0023,400031,150Jan 11 09:17 PM
Dallas Jayson Donald AlexanderDirectorDec 11Buy69.3153476,635Dec 15 04:07 PM
Dallas Jayson Donald AlexanderDirectorDec 08Buy66.2553316,630Dec 09 04:03 PM
Munshi AmitPresident and CEODec 08Sale70.006,517456,1987,750Dec 09 04:02 PM
Lisicki RobertEVP, Chief Commercial OfficerDec 01Sale66.063,872255,7860Dec 03 04:02 PM
Lisicki RobertEVP, Chief Commercial OfficerNov 25Option Exercise0.006,30006,300Nov 30 04:02 PM
Cabell ChristopherEVP, Head of R&D, and CMONov 25Option Exercise0.002,50002,500Nov 30 04:01 PM
Munshi AmitPresident and CEONov 25Option Exercise0.0011,700019,450Nov 30 04:00 PM
Aurentz VincentExecutive VP and CBONov 25Option Exercise0.009,00009,000Nov 30 04:00 PM